Skip to content
Careers
Contact Us
Linkedin
Twitter
Search for:
Home
About
The COUR Team
Medical & Science Partners
Product Development
Pipeline
CNP-101/TAK-101 (Celiac Disease)
CNP-201 (Peanut Allergy)
CNP-104 (Primary Biliary Cholangitis)
CNP-T1D (Type 1 Diabetes)
CNP-MYG (Myasthenia Gravis)
CNP-ITP (Immune Thrombocytopenia Purpura)
Technology
COUR Nanoparticle Platform
Immune Reprogramming
Therapeutic Areas
Autoimmune Diseases: Celiac
Food & Environmental Allergies: Peanut Allergy
Rare Diseases: Primary Biliary Cholangitis
Autoimmune Diseases: Type 1 Diabetes
Rare Diseases: Myasthenia Gravis
Rare Diseases: Immune Thrombocytopenia Purpura
Protein Replacement: Gene Therapy
Partners & Collaborators
Media & Publications
Press Releases
Scientific Publications
Corporate Deck
Videos
Technology
Autoimmune Disease
Food and Environmental Allergies
Gene Therapy
Presentation: Phase 2 Celiac Disease Data from UEG Week 2019
Presentation: Phase 2 Celiac Disease Data from UEG Week 2019
View Presentation Here
Post navigation
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Leave a Reply
Cancel reply
You must be
logged in
to post a comment.
